Results 291 to 300 of about 388,969 (398)

A Randomized, Placebo‐Controlled Trial of Hydroxychloroquine in Incomplete Lupus

Arthritis &Rheumatology, EarlyView.
Objective Patients with features of systemic lupus erythematosus (SLE) who do not fulfill classification criteria can be designated as incomplete lupus erythematosus (ILE). This condition includes individuals with a high risk of progression to SLE. Treatment of ILE may reduce symptoms, severity, and incidence of SLE.
Nancy J. Olsen, Duanping Liao, Judith A. James, Joel M. Guthridge, Cristina Arriens, Diane Kamen, Mariko Ishimori, Daniel J. Wallace, Christopher Striebich, Sonali Narain, Benjamin F. Chong, Fan He, Eric W. Schaefer, Vernon M. Chinchilli, David R. Karp   +14 more
wiley   +1 more source

Mucin-degrading gut bacteria: context-dependent roles in intestinal homeostasis and disease. [PDF]

Gut Microbes
Tiffany E, Kim KS, Sittipo P, Lee DW, Lee YK.   +4 more
europepmc   +1 more source

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source

CPA3 drives the development of asthma by promoting the activation of the JAK/STAT6 pathway. [PDF]

Respir Res
Wang K, Wu R, Fan M, Jia R, Liu Y, Li Y, Li P, Wang Y, Jiang T, Cheng Z.   +9 more
europepmc   +1 more source

Long‐term impact of Elexacaftor/Tezacaftor/ivacaftor on pulmonary, nutritional and metabolic outcomes in homozygous F508del cystic fibrosis patients: A real‐world cohort study

British Journal of Clinical Pharmacology, EarlyView.
Aim Elexacaftor/tezacaftor/ivacaftor (ETI) has markedly improved cystic fibrosis (CF) outcomes. However, its long‐term impact on nutrition, metabolism and liver health remains underexplored. We assessed 30‐month changes in pulmonary, nutritional, metabolic and inflammatory markers in people with CF (PwCF) homozygous for F508del.
Nicola Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Anna Virgilio, Giulia Amato, Giuseppe Cimino   +5 more
wiley   +1 more source

IPEC-J2 as a cellular model for studying intestinal mucus. [PDF]

Sci Rep
Dessauge F, Vincent A, Trefeu C, Mayeur-Nickel F, Wiart-Letort S, Macierzanka A, Beaumont M, Grundy MM.   +7 more
europepmc   +1 more source

Artificial mucus layer formed in response to ROS for the oral treatment of inflammatory bowel disease

G G Zhang, Dandan Song, Ruilong Ma, Mo Li, Bingyang Liu, Zhonggui He, Qiang Fu   +6 more
openalex   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, EarlyView.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Modeling tissue-scale ciliary transport and mixing in three-dimensional Newtonian flow. [PDF]

PLoS Comput Biol
Xu L, Senaei P, Jiang Y.
europepmc   +1 more source

Natural Family Planning - 40 Years of Reflections and Hopes [PDF]

, 1984
Carter, Patricia A.
core   +1 more source